CATALYST PHARMACEUTICALS, INC. 8-K

What Happened
Catalyst Pharmaceuticals, Inc. (CPRX) filed an 8-K (Item 8.01) on March 18, 2026 reporting that the U.S. District Court for the District of New Jersey issued an order delaying the start of the bench trial in its case against Hetero USA, Inc. The trial — which centers on the validity of Catalyst’s Orange Book‑listed patents for FIRDAPSE® — was moved from March 23, 2026 to May 18, 2026.

Key Details

• Court order filed: March 18, 2026 (District Court for the District of New Jersey).
• New bench trial start date: May 18, 2026 (previously scheduled for March 23, 2026).
• Parties: Catalyst Pharmaceuticals, Inc. v. Hetero USA, Inc.
• Patents at issue: Orange Book-listed patents covering FIRDAPSE® with expirations in 2032, 2034, and 2037.

Why It Matters
The filing changes the timing of a key patent validity trial that concerns FIRDAPSE® exclusivity. Because the case addresses patents listed in the Orange Book (expiring in 2032, 2034 and 2037), the trial’s schedule affects when the companies and investors will learn whether those patents will remain enforceable. This update is purely a scheduling change reported under Item 8.01; the filing does not report any court rulings or changes to the patents themselves.